About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Hepatic Oncology
›
Top Articles
Hepatic Oncology
Oncology
4
(top 4%)
Impact Factor
4.5
(top 4%)
extended IF
19
(top 18%)
H-Index
115
authors
138
papers
1K
citations
410
citing journals
1.3K
citing authors
Most Cited Articles of Hepatic Oncology
Title
Year
Citations
Molecular classification of hepatocellular carcinoma: potential therapeutic implications
2015
78
Mechanisms of doxorubicin resistance in hepatocellular carcinoma
2016
77
Hepatocellular carcinoma treatment: hurdles, advances and prospects
2018
38
Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress
2015
35
Biomarker development for hepatocellular carcinoma early detection: current and future perspectives
2017
35
JAK/STAT signaling in hepatocellular carcinoma
2020
32
STAT3 in hepatocellular carcinoma: new perspectives
2014
30
Dysregulated fatty acid metabolism in hepatocellular carcinoma
2016
29
The role of the innate immune system in the development and treatment of hepatocellular carcinoma
2020
25
RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma
2016
25
Systemic treatments for hepatocellular carcinoma: challenges and future perspectives
2018
24
Molecular classification of hepatocellular adenomas: impact on clinical practice
2018
24
Locoregional therapies in cholangiocarcinoma
2017
23
Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review
2020
21
Malignant transformation of hepatocellular adenoma
2014
19
Updates of colorectal cancer liver metastases therapy: review on DEBIRI
2020
17
Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies
2020
16
Radiologic criteria of response to systemic treatments for hepatocellular carcinoma
2017
15
The role of AEG-1 in the development of liver cancer
2015
15
Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial
2014
14
A perspective on molecular therapy in cholangiocarcinoma: present status and future directions
2014
14
Hepatic mesenchymal hamartoma and undifferentiated embryonal sarcoma of the liver: a pathologic review
2020
13
How Rap and its GEFs control liver physiology and cancer development. C3G alterations in human hepatocarcinoma
2018
12
Targeting glucose metabolism in cancer: new class of agents for loco-regional and systemic therapy of liver cancer and beyond?
2016
12
Apoptosis in liver carcinogenesis and chemotherapy
2015
12
0
1
2
next
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.